by Lim, Kwu JinPosted : April 29, 2026, 09:37Updated : April 29, 2026, 09:37
Samsung Biologics’ labor dispute has moved toward a strike, with disruptions already reported in some processes and the possibility of a broader walkout being discussed. The issue should not be dismissed as a routine company dispute, but it also should not be exaggerated into a “national crisis.” The central task is to uphold the principle of autonomous bargaining at a private company while finding a balanced approach that accounts for potential spillover effects across the industry.
First, the basic principle should be clear: A company is a private entity, and labor-management negotiations are fundamentally voluntary. Talks over wages, bonuses and working conditions are a matter of reconciling interests between the parties. Framing the dispute as “public interest” to pressure one side is difficult to justify. Workers’ right to strike is also protected by the Constitution.
Samsung Biologics Plant 4. (Yonhap)
Still, this dispute has features that set it apart. Contract manufacturing of biopharmaceuticals depends on long-term trust and quality certification. Production disruptions can go beyond short-term revenue losses, affecting contract stability and a company’s reputation. That can ripple to partners, investors and the local economy. In other words, while the dispute is private, the industry’s external impact is large, and public-interest considerations may also need to apply.
Even so, that does not justify assigning blame to only one side. It is not persuasive to label union demands “excessive” simply because a strike burdens the company. At the same time, management cannot avoid responsibility if it allowed conflict to escalate in an industry where stable production is critical. In sectors with high systemic risk, managing disputes early and drawing out compromise is a core management function.
The view that worker compensation and future investment are a simple trade-off also warrants review. Corporate capital allocation is complex. It cannot be assumed that wage increases automatically lead to cuts in research and development. Conversely, it also cannot be ruled out that excessive short-term compensation could squeeze investment capacity. The key is not simply raising or lowering one item, but designing a balanced allocation of overall resources. Labor and management should seek a practical meeting point on that basis.
A solution is not found in “dialogue” alone. For talks to work, institutional support is needed, and that is where the government’s role begins. The government cannot directly intervene in wage levels or management rights. But it can create a framework for mediation and conditions that allow negotiations to continue. Options could include procedures that encourage intensive bargaining for a set period, minimum operating standards for essential processes, and a system to assess public-interest impacts if the dispute drags on. Such measures could reduce industrial shock without undermining bargaining autonomy.
Another key issue is transparency. When wage demands, business performance and investment plans are disconnected, rational judgment is difficult. The company should present financial conditions and investment plans more clearly, and the union should explain the basis for its demands in concrete terms. When information is shared, negotiations can be driven by numbers rather than emotion.
Ultimately, the core issue is balance: workers’ rights, corporate sustainability and industrial stability must all be weighed. Emphasizing only one side will not produce a solution. A strike should be a last resort, and management should also leave room for compromise to the end.
What is needed now is not a test of strength, but restoring trust and finding a realistic compromise. The Samsung Biologics dispute may be part of the growing pains of a maturing Korean industry. If it is not managed, it could become a broader crisis; if resolved well, it could help establish a new balance. Neither side is free of responsibility.
